X4 Pharmaceuticals, Inc. XFOR
3.01
0.01
0.33%
as of 25 Sep
- Market cap
- $297.4M
- P/E
- 0.0×
Follow XFOR
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(156.87%) | (75.99%) | (104.21%) | (113.08%) | |
| (55.66%) | (36.25%) | (49.82%) | (50.32%) | ||
ROIC |
(399.12%) | (566.65%) | (543.03%) | (226.62%) | |
Return on Tangible Assets |
(86.83%) | (33.56%) | (45.67%) | (45.16%) | |
Average Days of Receivables |
17.25 | 5.96 | 45.07 | 47.15 | |
Free Cash Flow per Share |
(2.45) | (2.10) | (0.74) | (0.70) | |
Free Cash Flow |
(106.09) | (88.62) | (92.85) | (88.74) | |
Capital Expenditures |
(3.00) | (3.00) | — | (5.00) | |
Piotroski F-Score |
0.00 | 3.00 | 3.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(39.67%) | (16.61%) | (19.40%) | (19.02%) | |
Accounts Receivable Turnover |
25.37 | 30.76 | 7.88 | 8.10 | |
Accounts Payable Turnover |
0.84 | 0.80 | 0.20 | 0.50 | |
Inventory Turnover |
1.75 | 1.58 | 0.42 | 0.68 | |
Average Days of Payables |
323.85 | 361.13 | 1,129.74 | 490.07 | |
Days of Inventory on Hand |
261.49 | 283.97 | 1,032.64 | 685.40 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
223.39% | 207.11% | 772.80% | 418.92% | |
Selling, General and Administrative Expense of Revenue |
150.91% | 123.93% | 393.40% | 217.30% | |
Share Based Compensation of Revenue |
12.49% | 12.24% | 68.69% | 53.83% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.08 | 1.08 | 0.93 | 0.93 | |
Depreciation/Fixed assets |
6.09 | 7.02 | 7.01 | 15.01 | |
Capex/Depreciation |
(2.26) | (2.35) | 0.00 | (3.00) | |
Revenue per Share |
0.79 | 0.83 | 0.07 | 0.13 | |
Operating CF per Share |
(2.38) | (2.02) | (0.74) | (0.66) | |
Capex per Share |
(0.07) | (0.07) | 0.00 | (0.04) | |
Capex to Sales |
0.09 | 0.09 | 0.00 | 0.32 | |
Net Profit Margin |
(279.86%) | (225.55%) | (1,106.30%) | (568.80%) |
Columns are period end dates